Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
L19-IL2
DRUG
2 trials
Sponsors
Maastricht Radiation Oncology
Conditions
Limited Metastatic Disease
NSCLC Stage IV
Solid Tumour
Phase 1
Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor
Completed
NCT02086721
Maastricht Radiation Oncology
Solid Tumour
Start: 2015-12-31
End: 2017-05-31
Updated: 2017-05-31
Phase 2
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
Withdrawn
NCT02735850
Maastricht Radiation Oncology
Limited Metastatic Disease, NSCLC Stage IV
Start: 2015-12-31
End: 2021-06-30
Updated: 2017-05-23
Related Papers
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
2020-06-15
44 citations
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
OncoImmunology
2017-12-18
49 citations
Radiotherapy Triggers Durable Immunotherapy Responsiveness
Oncology Times
2016-08-30
1 citations
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
OncoImmunology
2015-04-02
22 citations
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Clinical Cancer Research
2014-12-31
101 citations